四乙基氯化铵一水合物 | 68696-18-4

• 物质功能分类: 化学试剂 - 有机试剂 - 胺盐（铵盐）
• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: 四乙基氯化铵一水合物
• 中文别名: 四乙基氯化铵，一水；四乙基氯化铵,一水
• 英文名称: tetraethylammonium chloride monohydrate
• 英文别名: tetraethylammmonium chloride monohydrate；tetraethylammonium chloride hydrate；tetraethylazanium;chloride;hydrate
• CAS: 68696-18-4
• 化学式: C₈H₂₀N*Cl*H₂O
• 分子量: 183.722
• InChiKey: CALLTGJPWMIDPC-UHFFFAOYSA-M

物化性质

• 熔点：
  ca 110℃
• 密度：
  1.0801
• 溶解度：
  1410g/l
• 稳定性/保质期：
  远离氧化物。

计算性质

• 辛醇/水分配系数(LogP)：
  -1.94
• 重原子数：
  11
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  1
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• TSCA：
  Yes
• 危险品标志：
  Xn
• 安全说明：
  S26,S36
• 危险类别码：
  R36/37/38
• WGK Germany：
  3
• RTECS号：
  BS6125000
• 海关编码：
  2923900090
• 危险标志：
  GHS07
• 危险性描述：
  H302,H315,H319,H335
• 危险性防范说明：
  P261,P305 + P351 + P338
• 储存条件：
  存放在密封容器中，并置于阴凉、干燥处。存储地点须远离氧化剂，以防接触湿气和水源。

SDS

---

Section 1. Chemical Product and Company Identification
Tet r aet hylammonium c h l o r i d e , Catalog
Common Name/
Number(s).
Trade Name
monohydrate
68696-18-4; 56-34-8
CAS#
(anhydrous)
Tetraethylammonium chloride, monohydrate

---

Section 3. Hazards Identification
Hazardous in case of skin contact (irritant), of eye contact (irritant). Slightly hazardous in case of ingestion, of
Potential Acute Health
inhalation.
Effects
CARCINOGENIC EFFECTS: Not available.
Potential Chronic Health
MUTAGENIC EFFECTS: Not available.
Effects
TERATOGENIC EFFECTS: Not available.
DEVELOPMENTAL TOXICITY: Not available.
Repeated or prolonged exposure is not known to aggravate medical condition.

---

Section 4. First Aid Measures
Check for and remove any contact lenses. In case of contact, immediately flush eyes with plenty of water for at least
Eye Contact
15 minutes. Cold water may be used. Get medical attention.
In case of contact, immediately flush skin with plenty of water. Cover the irritated skin with an emollient. Remove
Skin Contact
contaminated clothing and shoes. Cold water may be used.Wash clothing before reuse. Thoroughly clean shoes
before reuse. Get medical attention.
Serious Skin Contact Not available.
If inhaled, remove to fresh air. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get
Inhalation
medical attention.
Serious Inhalation Not available.
Do NOT induce vomiting unless directed to do so by medical personnel. Never give anything by mouth to an
Ingestion
unconscious person. Loosen tight clothing such as a collar, tie, belt or waistband. Get medical attention if symptoms
appear.
Serious Ingestion Not available.

---

Section 5. Fire and Explosion Data
Flammability of the Product May be combustible at high temperature.
Auto-Ignition Temperature Not available.
Not available.
Flash Points
Not available.
Flammable Limits
These products are carbon oxides (CO, CO2), nitrogen oxides (NO, NO2...), halogenated compounds.
Products of Combustion
Fire Hazards in Presence of Slightly flammable to flammable in presence of heat.
Various Substances
Risks of explosion of the product in presence of mechanical impact: Not available.
Explosion Hazards in
Risks of explosion of the product in presence of static discharge: Not available.
Presence of Various
Substances
SMALL FIRE: Use DRY chemical powder.
Fire Fighting Media
LARGE FIRE: Use water spray, fog or foam. Do not use water jet.
and Instructions
Not available.
Special Remarks on
Fire Hazards
Not available.
Special Remarks on
Explosion Hazards
Tetraethylammonium chloride, monohydrate

---

Section 6. Accidental Release Measures
Use appropriate tools to put the spilled solid in a convenient waste disposal container. Finish cleaning by spreading
Small Spill
water on the contaminated surface and dispose of according to local and regional authority requirements.
Use a shovel to put the material into a convenient waste disposal container. Finish cleaning by spreading water on
Large Spill
the contaminated surface and allow to evacuate through the sanitary system.

---

Section 7. Handling and Storage
Keep away from heat. Keep away from sources of ignition. Ground all equipment containing material. Do not
Precautions
ingest. Do not breathe dust. If ingested, seek medical advice immediately and show the container or the label.
Keep away from incompatibles such as oxidizing agents.
Keep container tightly closed. Keep container in a cool, well-ventilated area.
Storage

---

Section 8. Exposure Controls/Personal Protection
Use process enclosures, local exhaust ventilation, or other engineering controls to keep airborne levels below
Engineering Controls
recommended exposure limits. If user operations generate dust, fume or mist, use ventilation to keep exposure to
airborne contaminants below the exposure limit.
Personal Protection Safety glasses. Lab coat. Dust respirator. Be sure to use an approved/certified respirator or equivalent. Gloves.
Personal Protection in Case Splash goggles. Full suit. Dust respirator. Boots. Gloves. A self contained breathing apparatus should be used to
avoid inhalation of the product. Suggested protective clothing might not be sufficient; consult a specialist BEFORE
of a Large Spill
handling this product.
Exposure Limits Not available.

---

Section 9. Physical and Chemical Properties
Solid. (Deliquescent solid. Crystalline solid.) Not available.
Physical state and O dor
appearance
Not available.
Taste
183.72 g/mole
Molecular Weight
Colorless to light yellow.
Color
Not available.
pH (1% soln/water)
Not available.
Boiling Point
94°C (201.2°F) 102 C.
Melting Point
Not available.
Critical Temperature
Not available.
Specific Gravity
Not applicable.
Vapor Pressure
Not available.
Vapor Density
Not available.
Volatility
Not available.
Odor Threshold
Not available.
Water/Oil Dist. Coeff.
Not available.
Ionicity (in Water)
See solubility in water.
Dispersion Properties
Easily soluble in cold water.
Solubility
Tetraethylammonium chloride, monohydrate

---

Section 10. Stability and Reactivity Data
The product is stable.
Stability
Not available.
Instability Temperature
Conditions of Instability Excess heat, incompatible materials
Incompatibility with various Reactive with oxidizing agents.
substances
Non-corrosive in presence of glass.
Corrosivity
Not available.
Special Remarks on
Reactivity
Not available.
Special Remarks on
Corrosivity
Will not occur.
Polymerization

---

Section 11. Toxicological Information
Inhalation. Ingestion.
Routes of Entry
Acute oral toxicity (LD50): 833 mg/kg [Mouse].
Toxicity to Animals
Chronic Effects on Humans Not available.
Other Toxic Effects on Hazardous in case of skin contact (irritant).
Humans Slightly hazardous in case of ingestion, of inhalation.
Not available.
Special Remarks on
Toxicity to Animals
Not available.
Special Remarks on
Chronic Effects on Humans
Special Remarks on other Acute Potential Health Effects:
Toxic Effects on Humans Skin: Causes skin irritation.
Eyes: Causes eye irritation.
Inhalation: May cause respiratory tract irritation.
Ingestion: May cause nausea, vomiting, diarrhea. May affect behavior/central nervous system/peripheral nervous
system (paresthesis, flaccid paralysis, change in motor activity, muscle weakness, somnolence, tremor, ataxia),
respiration (respiratory depression).

---

Section 12. Ecological Information
Not available.
Ecotoxicity
Not available.
BOD5 and COD
Products of Biodegradation Possibly hazardous short term degradation products are not likely. However, long term degradation products may
arise.
The products of degradation are more toxic than the product itself.
Toxicity of the Products
of Biodegradation
Not available.
Special Remarks on the
Products of Biodegradation
Tetraethylammonium chloride, monohydrate

---

Section 13. Disposal Considerations
Waste must be disposed of in accordance with federal, state and local environmental control
Waste Disposal
regulations.

---

Section 14. Transport Information
Not a DOT controlled material (United States).
DO T Cl assi fi cati on
Not applicable.
Identification
Not applicable.
Special Provisions for
Transport
DO T (Pi ctograms)

---

Section 15. Other Regulatory Information and Pictograms
No products were found.
Federal and State
Regulations
California prop. 65: This product contains the following ingredients for which the State of California has found to
California
cause cancer which would require a warning under the statute: No products were found.
Proposition 65
Warnings
California prop. 65: This product contains the following ingredients for which the State of California has found to
cause birth defects which would require a warning under the statute: No products were found.
Other Regulations EINECS: This product is not on the European Inventory of Existing Commercial Chemical Substances.
Canada: Not listed on Canadian Domestic Substance List (DSL) or Canadian Non- Domestic Substance List (NDSL).
China: Not listed on National Inventory.
Japan: Not listed on National Inventory (ENCS).
Korea: Not listed on National Inventory (KECI).
Philippines: Not listed on National Inventory (PICCS).
Australia: Not listed on AICS.
WHMIS (Canada) CLASS D-2B: Material causing other toxic effects (TOXIC).
Other Classifications
R36/38- Irritating to eyes and skin. S26- In case of contact with eyes, rinse
DSCL (EEC)
immediately with plenty of water and seek
medical advice.
S28- After contact with skin, wash immediately
with plenty of water.
S37/39- Wear suitable gloves and eye/face
protection.
Health Hazard
HMIS (U.S.A.) 2 National Fire Protection
1 Flammability
1 Association (U.S.A.)
Fire Hazard
1 0 Reactivity
Health
Reactivity 0
Specific hazard
Personal Protection
E
WHMIS (Canada)
(Pictograms)
Tetraethylammonium chloride, monohydrate
DSCL (Europe)
(Pictograms)
TDG(Canada)
(Pictograms)
ADR (Europe)
(Pictograms)
Protective Equipment
Gloves.
Lab coat.
Dust respirator. Be sure to use an
approved/certified respirator or equivalent.
Wear appropriate respirator when ventilation
is inadequate.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  四乙基氯化铵一水合物 以 四氢呋喃 、 二乙二醇二甲醚 为溶剂， 生成
  参考文献：
  名称：

  晶体学测定反式配体对三苯基膦键合的影响。Cr（CO）4（PPh3）L（L = PBu3，P（OMe）3和P（OPh）3）的晶体和分子结构

  摘要：

  DOI：

  10.1021/om00124a012
• 作为试剂：
  描述：

  2-溴苯酚 在 四乙基氯化铵一水合物 、 sodium formate 、 sodium acetate 、 palladium diacetate 、 四丁基碘化铵 、 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 28.0h， 生成 3,3-二甲基-2H-苯并呋喃
  参考文献：
  名称：

  DNA-PK INHIBITORS

  摘要：

  本发明涉及作为DNA-PK抑制剂的化合物。该发明还提供了包含所述化合物的药物可接受的组合物，以及使用所述组合物治疗各种疾病、状况或失调的方法。

  公开号：

  US20130281431A1

文献信息

• Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases
  申请人：Vertex Pharmaceuticals Incorporated

  公开号：US20150231142A1

  公开（公告）日：2015-08-20

  The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

  本发明涉及含有上皮钠通道活性抑制剂与至少一种ABC转运蛋白调节剂化合物（A式、B式、C式或D式）的药物组合物。该发明还涉及这些药物配方，以及使用这些组合物治疗CFTR介导的疾病，特别是囊性纤维化的方法。
• COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES
  申请人：Van Goor Fredrick F.

  公开号：US20110098311A1

  公开（公告）日：2011-04-28

  The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

  本发明涉及包含上皮钠通道活性抑制剂与至少一种ABC转运蛋白调节剂化合物（A式、B式、C式或D式）的药物组合物。该发明还涉及这些药物配方，以及使用这些组合物治疗CFTR介导的疾病，特别是囊性纤维化的方法。
• Organometallic chemistry in a conventional microwave oven: the facile synthesis of group 6 carbonyl complexes
  作者：Michael Ardon、Graeme Hogarth、Daniel T.W Oscroft

  DOI：10.1016/j.jorganchem.2004.04.030

  日期：2004.8

  however, this reaction requires an inert atmosphere. While W(CO)6 reacts rapidly with amines to give cis diamine adducts in high yields, direct reactions with phosphines are not so clean. Bis(phosphine) complexes are, however, cleanly formed when a small amount of piperidine is added to the reaction mixture, presumably via the bis(piperidine) complex cis-[W(CO)4(pip)2]. Reactions with Cr(CO)6 generally

  通过在改进的常规微波炉中进行反应，可以改善，加速和简化通过回流进行的合成。为了证明这种方法的潜力，据报道合成了20多种第6组有机金属化合物。六羰基，最著名的是Mo（CO）6，在改良的常规微波炉中与一定范围的单，双和三齿配体反应。它们通常在没有惰性气氛的情况下进行，产率高且反应时间短。例如，在20分钟内以大于95％的收率制备顺式[[Mo（CO）4（dppe）]。Mo（CO）6与二环戊二烯的反应可简单地一步合成[CpMo（CO）3 ]。2个在> 90％的产率，这与在甲苯中的炔烃以产生dimetallatetrahedrane衍生物进一步反应，混合[Cp 2沫2（CO）4（μ-RC 2 R）]; 大概是通过原位形成对空气敏感的[CpMo（CO）2 ] 2来实现的。还可以在45分钟内以48％的收率制备四乙酸二钼酸乙酯，但是，该反应需要惰性气氛。W（CO）6与胺快速反应以高产率生成顺式二胺加合物，但
• Vanilloid receptor ligands and their use in treatments
  申请人：——

  公开号：US20030195201A1

  公开（公告）日：2003-10-16

  Compounds having the general structure 1 and compositions containing them, for the treatment of acute, inflammatory and neuropathic pain, dental pain, general headache, migraine, cluster headache, mixed-vascular and non-vascular syndromes, tension headache, general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, inflammatory pain and associated hyperalgesia and allodynia, neuropathic pain and associated hyperalgesia and allodynia, diabetic neuropathy pain, causalgia, sympathetically maintained pain, deafferentation syndromes, asthma, epithelial tissue damage or dysfunction, herpes simplex, disturbances of visceral motility at respiratory, genitourinary, gastrointestinal or vascular regions, wounds, burns, allergic skin reactions, pruritis, vitiligo, general gastrointestinal disorders, gastric ulceration, duodenal ulcers, diarrhea, gastric lesions induced by necrotising agents, hair growth, vasomotor or allergic rhinitis, bronchial disorders or bladder disorders.

  具有一般结构1的化合物以及含有它们的组合物，用于治疗急性疼痛、炎症性和神经性疼痛、牙痛、普通头痛、偏头痛、丛集性头痛、混合性血管和非血管综合症、紧张性头痛、一般炎症、关节炎、风湿病、骨关节炎、炎症性肠病、炎症性眼病、炎症性或不稳定的膀胱病、银屑病、具有炎症成分的皮肤疾病、慢性炎症状况、炎症性疼痛及其相关的过度疼痛和异常疼痛、神经性疼痛及其相关的过度疼痛和异常疼痛、糖尿病性神经病疼痛、灼痛、交感神经维持的疼痛、去神经综合症、哮喘、上皮组织损伤或功能障碍、单纯疱疹、在呼吸、生殖泌尿、胃肠或血管区域的内脏运动障碍、伤口、烧伤、过敏性皮肤反应、瘙痒、白癜风、一般胃肠病、胃溃疡、十二指肠溃疡、腹泻、由坏死性剂引起的胃部病变、毛发生长、血管运动性或过敏性鼻炎、支气管障碍或膀胱障碍。
• Chemokine receptor binding heterocyclic compounds with enhanced efficacy
  申请人：——

  公开号：US20030220341A1

  公开（公告）日：2003-11-27

  The invention relates to heterocyclic compounds consisting of a core nitrogen atom surrounded by three pendant groups, wherein two of the three pendant groups are preferably benzimidazolyl methyl and tetrahydroquinolyl, and the third pendant group contains N and optionally contains additional rings. The compounds bind to chemokine receptors, including CXCR4 and CCR5, and demonstrate protective effects against infection of target cells by a human immunodeficiency virus (HIV).

  这项发明涉及由一个核心氮原子环绕着三个侧链基团的杂环化合物，其中三个侧链基团中的两个最好是苯并咪唑甲基和四氢喹啉基，第三个侧链基团含有N，并且可选地含有额外的环。这些化合物与趋化因子受体结合，包括CXCR4和CCR5，并且表现出对人类免疫缺陷病毒（HIV）感染靶细胞的保护作用。